Fate Therapeutics Inc

NASDAQ:FATE  
71.62
+5.11 (+7.68%)
4:13:14 PM EDT: $72.27 +0.65 (+0.91%)
Earnings Announcements

Fate Therapeutics Announces Positive Interim Clinical Data From FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

Published: 08/19/2021 21:53 GMT
Fate Therapeutics Inc (FATE) - Fate Therapeutics Announces Positive Interim Clinical Data From Its Ft596 and Ft516 Off-the-shelf, Ipsc-derived Nk Cell Programs for B-cell Lymphoma.
Fate Therapeutics Inc - 8 of 11 Patients in Ft516 Multi-dose Escalation Cohorts 2 and 3 Achieved Objective Response.
Fate Therapeutics Inc - 10 of 14 Patients in Ft596 Single-dose Escalation Cohorts 2 and 3 Achieved Objective Response.
Fate Therapeutics Inc - Ft596 and Ft516 Treatment Regimens Were Well-tolerated.
Fate Therapeutics Inc - No Dose-limiting Toxicities, and No Adverse Events of Any Grade of Icans Or Gvhd, Were Observed.
Fate Therapeutics Inc - Two Low-grade Adverse Events of Crs Were Reported in Ft596 Single-dose Escalation Cohorts 1 and 2.
Revenue is expected to be $8.1 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $9.52 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.